FindTrial
Sign In

Placebo for guselkumab

DRUG6 trials

Sponsors

Janssen - Cilag International, Janssen Research & Development, LLC

Conditions

Moderately to Severely Active Crohn's DiseasePsoriasis

Phase 2

A Phase 2/3, Randomized, Double-blind, Placebo-and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease
Active, not recruitingCTIS2023-504736-18-00
Janssen - Cilag InternationalModerately to Severely Active Crohn's Disease
Start: 2018-07-26Target: 474Updated: 2026-01-23

Phase 3

A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab
CompletedNCT02203032
Janssen Research & Development, LLCPsoriasis
Start: 2014-10-07End: 2016-05-24Updated: 2017-09-12
A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis
CompletedNCT02207231
Janssen Research & Development, LLCPsoriasis
Start: 2014-11-26End: 2020-06-17Updated: 2021-07-23
A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment
CompletedNCT02207244
Janssen Research & Development, LLCPsoriasis
Start: 2014-11-03End: 2020-07-01Updated: 2021-07-22
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
Active, not recruitingNCT03451851
Janssen Research & Development, LLCPsoriasis
Start: 2018-07-11End: 2026-12-18Updated: 2026-03-12
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Crohn's Disease
Active, not recruitingCTIS2023-504737-41-00
Janssen - Cilag InternationalModerately to Severely Active Crohn's Disease
Start: 2022-06-10Target: 219Updated: 2026-01-19

Related Papers

Extrapolating Guselkumab Efficacy to Juvenile Psoriatic Arthritis from Adult Psoriatic Arthritis and Adult and Pediatric Psoriasis Data.
2025-10-28
Comparative Efficacy of Deucravacitinib and Adalimumab for Scalp Psoriasis: An Indirect Treatment Comparison.
2025-08-01
Psoriasis im Kindes- und Jugendalter: Zwischen Off-Label-Therapie und Zulassung
Kompass Dermatologie2025-07-24
Guselkumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients: results of the phase III randomized placebo-controlled PROTOSTAR study
British Journal of Dermatology2024-12-211 citations
Efficacy of Brodalumab in Patients with Psoriasis and Risk Factors for Treatment Failure: A Review of Post Hoc Analyses.
2024-09-124 citations
Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical Trial.
2024-08-171 citations
Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 Substudy.
2024-06-053 citations
Response Types and Factors Associated with Response Types to Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis from Two Randomized Clinical Trials.
2024-03-155 citations
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis.
2023-10-3131 citations
Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial
American Journal of Clinical Dermatology2023-10-074 citations
Five-year Maintenance of Clinical Response and Consistent Safety Profile for Guselkumab in Asian patients with Psoriasis from VOYAGE 1 and VOYAGE 2.
2023-09-261 citations
Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis.
2023-09-157 citations
Nail psoriasis dynamics during biologic treatment and withdrawal in patients with psoriasis who may be at high risk of developing psoriatic arthritis: a post hoc analysis of the VOYAGE 2 randomized trial.
2023-09-153 citations
Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study.
2020-12-0122 citations
Biologics in Pediatric Psoriasis and Atopic Dermatitis: Revolutionizing the Treatment Landscape
Cutis2020-11-011 citations
Work/study productivity gain and associated indirect cost savings with guselkumab compared with adalimumab in moderate-to-severe psoriasis: results from the VOYAGE 1 study.
2020-04-168 citations
Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2.
2019-10-214 citations
Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies.
2019-05-0149 citations
Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies.
2019-02-0131 citations
Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions
JAMA Dermatology2018-05-17117 citations